RDUS News and Press, Radius Health Inc. From 06/22/22

Italian pharma giant Menarini Group and Radius Health (NASDAQ:RDUS) on Wednesday said they had submitted a new drug application to the U.S. FDA for their drug elacestrant to treat breast cancer. RDUS' elacestrant, which has been out-licensed to Menarini, is intended for the potentia...

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-month FDA review Positive EMERALD study data previously announced on October 20, 2021 First, and currently only, investigational ...

Presentation Highlights Lack of Alignment with Stockholders, Poor Corporate Governance, Entrenchment Tactics and Strategic Mismanagement as Reasons Why the Current Board Must Be Meaningfully Reconstituted Letter to Fellow Stockholders Details the Board’s Track Rec...

The commercial-stage biotech added more than 10% Thursday after hedge fund manager and one of the company’s major shareholder Rubric Capital Management announced its support for an activist slate of board members. Noting what it called “company’s underperformanc...

Outlines Value Enhancing Initiatives to Address Company’s Underperformance and Poor Corporate Governance Intends to Support Velan-Repertoire Director Slate at Upcoming Annual Meeting Rubric Capital Management LP (“Rubric”), an investment ...

Radius Touts its “Internal Activism” but the Facts Reveal a Conflicted Board that has Failed to Provide Proper Oversight of CEO Martin or Instill a Culture of Accountability Radius has Experienced a 49% Decline in Stock Price, 60% Employee Turnover and 10% ...

Radius Health (NASDAQ:RDUS) on Wednesday said it had entered into new agreements for the expansion of its Tymlos injection to treat osteoporosis - a condition in which bones become weak and brittle - in postmenopausal women. RDUS said it had entered into agreements with the following companie...

Globalization has been a key priority for the Company over the past two years Three additional market agreements now signed and executed: - Labatec Pharma SA: Switzerland, Middle East & North Africa (MENA) countries - Pharmbio Korea Inc.: South Korea - Biosidus: Colombia, ...

Sends Letter to Fellow Stockholders Detailing the Board’s Record of Persistent Value Erosion and Highlights Pathway to Unlock Tremendous Upside Potential Cites Lack of Alignment with Stockholders, Poor Corporate Governance, Entrenchment Tactics and Strategic Misma...

FLORENCE, Italy and BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the presentation at the 2022 American Society of Clinical...